Buprenorphine extended-release (XR) is an extended-release monthly injection to treat opioid use disorder (OUD). This retrospective case series includes 15 postpartum patients who were treated with buprenorphine-XR at a single center and reports on their outcomes. The average total daily sublingual buprenorphine dose before initiation of buprenorphine-XR was 16.25 mg (SD67.76, range 2–32 mg). Overall, 137 total doses of buprenorphine-XR were administered between May 17, 2021, and April 11, 2023. Urine toxicology test results were negative for opioids other than buprenorphine in the majority (80.0%) of patients once appropriate maintenance doses were achieved. Euphoria and intoxication were not reported. A minority of patients (20.0%) discontinued buprenorphine-XR. Although more extensive research is needed before widespread use, buprenorphine-XR may be a favorable treatment for OUD in this high-risk population.

Original languageEnglish
Pages (from-to)1148-1152
Number of pages5
JournalObstetrics and gynecology
Issue number5
StatePublished - Nov 1 2023


Dive into the research topics of 'Buprenorphine Extended-Release Treatment for Opioid Use Disorder in the Postpartum Period'. Together they form a unique fingerprint.

Cite this